BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX - Free Report) in a report published on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $20.00 target price on the biotechnology company's stock. Cantor Fitzgerald also issued estimates for BioCryst Pharmaceuticals' FY2025 earnings at ($0.27) EPS.

A number of other analysts have also recently commented on BCRX. Royal Bank of Canada reiterated an "outperform" rating and issued a $11.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, April 11th. Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective on the stock. Needham & Company LLC restated a "buy" rating and issued a $15.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, April 10th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Finally, JMP Securities restated a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $16.13.

BioCryst Pharmaceuticals Stock Up 2.5 %

BCRX traded up $0.22 on Tuesday, reaching $8.93. 4,418,295 shares of the company traded hands, compared to its average volume of 2,827,976. The company has a market cap of $1.87 billion, a P/E ratio of -14.64 and a beta of 1.08. BioCryst Pharmaceuticals has a one year low of $4.42 and a one year high of $9.50. The firm has a fifty day simple moving average of $7.69 and a two-hundred day simple moving average of $7.80.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. BioCryst Pharmaceuticals's quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.28 EPS. On average, equities analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC lifted its position in BioCryst Pharmaceuticals by 167.5% in the first quarter. CWM LLC now owns 53,750 shares of the biotechnology company's stock valued at $403,000 after acquiring an additional 33,656 shares during the last quarter. Cerity Partners LLC increased its position in shares of BioCryst Pharmaceuticals by 203.6% during the first quarter. Cerity Partners LLC now owns 36,410 shares of the biotechnology company's stock worth $273,000 after purchasing an additional 24,418 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter valued at about $79,000. Wealth Enhancement Advisory Services LLC boosted its position in shares of BioCryst Pharmaceuticals by 113.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 37,671 shares of the biotechnology company's stock valued at $283,000 after purchasing an additional 20,043 shares during the period. Finally, SG Americas Securities LLC grew its stake in BioCryst Pharmaceuticals by 5.2% during the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock worth $326,000 after buying an additional 2,146 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.